Royalty Pharma
About Royalty Pharma
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
- Founded
- 1996
- CEO
- Mr. Pablo Legorreta
- Employees
- 100
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- royaltypharma.com
Company profile
- Exchange
- US
- Symbol
- RPRX
- Market-cap rank
- #759
- Listing date
- 2020-06-16
- Market cap
- 30.48B
- Float cap
- 28.44B
- Shares out
- 445.27M
- Float shares
- 415.52M
Sectors & themes
Quote time 2026-11-20 20:02:28 · For reference only, not investment advice and not tailored to your situation.
Royalty Pharma discussion 0 comments